BRAF and colorectal carcinoma: Importantly, such complex sub-clonal architecture was observed not only in CRC cells treated with a single agent (such as EGFR inhibitor cetuximab or BRAF inhibitor dabrafenib), but also when combinatorial regimens of drugs targeting different pathways were administered.